Wockhardt Limited · NSE:WOCKPHARMA
Wockhardt — Investor Presentation (February 2007)
33 slides from Wockhardt's investor presentation, February 2007
Slide 1: Wockhardt Limited
XQ Wockhardt Limited
Slide 2: Slide 2
Slide 3: Overview
Overview ¾ Over 4 decades of Excellence in Pharma Business ¾ Leading Pharmaceutical and Biotechnology major Comprehensive capabilities - “Concept to Market” ¾ First Pharmaceutical Company in India to be selected as Business Super Brand ¾ Culture of creating world class organisation
Slide 4: Overview
Overview ¾ Global Footprints Successful acquisition track-record • Four acquisitions in Europe Two-third of the revenues from the international markets Europe is the largest business US business on a strong growth track ¾ 7000 Wockhardians across the globe 1000 Wockhardians outside India
Slide 5: Overview
Overview Sales $ 400mn Op. Margins 23 % PAT $ 68mn ROCE 28 % RONW 32 % R&D Spend @ 8 % of annual turnover
Slide 6: 10 year snapshot
10 year snapshot ¾ Sales Performance CAGR of 21% ¾ Profitability CAGR of 22% ¾ R&D investment CAGR of 28% ¾ IPO investor rewarded 27% Annualized returms
Slide 7: Global Footprints
Global Footprints ROW 8% EU & US Business constitutes India 35% more than 55% of total revenues Europe 47% USA 10% Business outside India as % of sales 80% 65% 60% Business outside India - key growth 40% 20% driver for Wockhardt 20% 10% 0% 1994 1999 2006
Slide 8: Wockhardt Advantage
Wockhardt Advantage R&D & Manufacturing Competitiveness Biopharmaceuticals & Generics Regulated India ROW Markets
Slide 9: Manufacturing Capabilities
Manufacturing Capabilities • Strategically located manufacturing facilities in India, UK and Ireland • Approved by major regulatory authorities including US FDA Steriles Vials, Ampoules, Cartridges, lyophilized products, Cephalosporins Biotech API’s: 3 major expression systems: yeast, e-coli, mammal
Slide 10: Research & Development
Research & Development
Slide 11: R&D - Model
R&D - Model Biotech New Chemical Research & Development Generics Entity
Slide 12: R&D - Overview
R&D - Overview Multi - disciplinary R&D Skilled Team IPR Creation Recombinant 450 Scientists biopharmaceuticals 100 PhD’s 200+ patents filed Generics in 2006 New Chemical Entity
Slide 13: Generics
Generics ¾ Vertically integrated model – 35+ DMF filings ¾ Filings in 3 strategic areas Injectables (Cephalosporins & Non-Cephalosporins) Blockbuster molecules going off-patent Value Added Generics (NDDS, Niche, follow-on Para IV) ¾ Product pipeline U.S. : 20+ U.K. : 20+ Germany : 15+
Slide 14: Biopharmaceuticals – Value Chain
Biopharmaceuticals – Value Chain IE S I T ABIL C AP SBU established KET R - Marketing in 10 countries MA TO Registrations P T C E - 50+ Registrations received Business ON -135+ registrations in C pipeline Established facilities for meeting global requirements Regulatory - Pilot plant - Biotech Plant
Slide 15: New Chemical Entity
New Chemical Entity ¾ Drug discovery team of 400 scientists 150 Ph.D.s ¾ Strategic focus on single therapeutic - Sepsis and Anti-infectives Develop comprehensive capabilities and competitive edge ¾ Program started in 1997 ¾ Early success, one molecule at proof of concept stage
Slide 16: New Chemical Entity - Pipeline
New Chemical Entity - Pipeline Preclinical Clinical NCE Indication Form Early Preclin. Adv. Preclin. Phase I Phase II MRSA, WCK 771 resistant IV infections Respiratory WCK 1152 Oral infections IV MRSA, WCK 2349 resistant Oral infections MRSA, WCK 2370 resistant Oral infections Gram +ve Oral WCK 2664
Slide 17: International Business
International Business
Slide 18: Wockhardt Ltd – Global Offices
Wockhardt Ltd – Global Offices Wockhardt UK Ltd, Wrexham) Russia (Wockhardt Russia Ltd, Moscow) Pinewood, Ireland Germany (esparma GmbH, Osterwedingen) USA (Wockhardt USA Inc, New York) Head Office – Mumbai, India Viet Nam (Wockhardt VietNam) Nigeria (Wockhardt Nigeria Ltd, Lagos) Brazil (Wockhardt
Slide 19: International Business
International Business ¾ International business is a key growth driver for Wockhardt CAGR of 46% over last 10 years International Business as % of sales 80% 65% 60% 40% 20% 20% 10% 0% 1994 1999 2006
Slide 20: International Business
International Business Footprints across major pharmaceutical markets ¾ Europe Wockhardt UK (CP Pharma, Wallis) Esparma, Germany Pinewood, Ireland ¾ USA Wockhardt USA ¾ ROW Countries Biopharmaceuticals
Slide 21: Europe
Europe Wockhardt UK Largest Indian generic company 2nd largest in the hospital business Amongst top 10 generic companies US FDA approved comprehensive manufacturing capabilities Esparma ¾ Innovatively structured acquisition in Germany in 2004 Entry in the largest European Generic market
Slide 22: Europe
Europe Pinewood ¾ Wockhardt’s largest acquisition till date (€117mn) Acquired on 1st Oct 06 ¾ Leader in the Irish generic market ¾ Liquid and Cream manufacturing facility ¾ Over 200 marketing authorizations
Slide 23: USA
USA ¾ Own sales and marketing organization in the US ¾ 17 products being marketed ¾ 8 manufacturing facilities approved by USFDA Across technologies (tablets, steriles, API) ¾ Robust pipeline underway US business to grow 30%+ in medium term
Slide 24: ROW
ROW ¾ Launch of Biopharmaceuticals in various ROW markets initiated Three pronged marketing and distribution strategy Sales & Mktg Strategic Joint Distribution Organization Ventures Partnerships ¾ Sales & marketing set up in major markets of erstwhile CIS, S E Asia, Latin America and North Africa
Slide 25: International Business – Growth Drivers
International Business – Growth Drivers Front-end Infrastructure in place in major markets • Germany:esparma GmbH Europe • UK: Wockhardt UK Ltd •Ireland: Pinewood International • Wockhardt US Inc. US Business • Aggressive ANDA programme • Biotech park commissioned ROW • Registrations in place • Mark
Slide 26: Indian Business
Indian Business
Slide 27: Indian Business - Overview
Indian Business - Overview ¾ 5 therapy focused marketing divisions 1200 field personnel catering to 1,50,000 doctors ¾ Strong Focus and Superior Product Mix Covers 47% of the therapeutic segments 6 brands Rank amongst the Top 300 of the Industry ¾ Young Portfolio Products launched <5 years c
Slide 28: Indian Business - Overview
Indian Business - Overview Creating Niche thru. Biotech & NDDS Products Biotech Diabetology • Growth of 54% in ‘05 • Wockhardt’s diabetology portfolio grew by 58% in 2005 • 3 successful products in market • Pioneer in Novel Delivery - EPO: Market Leader Systems for Oral Anti-Diabetic - rhu Insulin:
Slide 29: Indian Business - Diabetology Portfolio
Indian Business - Diabetology Portfolio COMPLETE DIABETOLOGY OFFERING 2005 2006 Wosulin Cartridges Wosulin Cartridges & Pens & Pens 2003 - 2004 Insulin - vials Insulin - vials Insulin - vials - Wosulin R - Wosulin R - Wosulin R - Wosulin 50/50 - Wosulin 50/50 - Wosulin 50/50 - Wosulin30/70 - Wosulin
Slide 30: www.wockhardtdiabetic.com
www.wockhardtdiabetic.com A dedicated website for diabetics www.wockhardtdiabetic.com
Slide 31: Indian Business - Growth Drivers
Indian Business - Growth Drivers ¾ Will continue to outperform the industry growth rate ¾ Biotech, Diabetology and Nephrology would continue to remain the key growth drivers ¾ New strategic group focusing on Specialty Nutrition created ¾ Focus on Power brands
Slide 32: Strategic Alliances
Strategic Alliances ¾ Amylin, U.S. ¾ Eli Lilly, U.S. ¾ Eisai, Japan ¾ Ebewe, Austria ¾ Gambro, Sweden ¾ Galpharm, UK ¾ LSI, UK ¾ Cell Therapeutics, U.S. ¾ AFT, New Zealand ¾ Ranbaxy, India Successful strategic alliances across the globe
Slide 33: Thank You
Thank You